Abstract:Question Does the hypoxic hypobaric environment of a high altitude increase the risk of cardiac arrhythmia? Findings In this cohort study, more than 1 in 3 participants experienced bradyarrhythmia or tachyarrhythmia during the ascent from basecamp to the summit of Mount Everest. The proportion of individuals with arrhythmia remained stable across levels of increasing altitude, while the majority of arrhythmias occurred when no supplemental bottled oxygen was used. Meaning The potential implications of the observed rhythm disturbances at high altitudes need to be explored in future studies. Importance Arterial hypoxemia, electrolyte imbalances, and periodic breathing increase the vulnerability to cardiac arrhythmia at altitude. Objective To explore the incidence of tachyarrhythmias and bradyarrhythmias in healthy individuals at high altitudes. Design, Setting, and Participants This prospective cohort study involved healthy individuals at altitude (8849 m) on Mount Everest, Nepal. Recruitment occurred from January 25 to May 9, 2023, and data analysis took place from June to July 2023. Exposure All study participants underwent 12-lead electrocardiogram, transthoracic echocardiography, and exercise stress testing before and ambulatory rhythm recording both before and during the expedition. Main Outcome The incidence of a composite of supraventricular (>30 seconds) and ventricular (>3 beats) tachyarrhythmia and bradyarrhythmia (sinoatrial arrest, second- or third-degree atrioventricular block). Results Of the 41 individuals recruited, 100% were male, and the mean (SD) age was 33.6 (8.9) years. On baseline investigations, there were no signs of exertional ischemia, wall motion abnormality, or cardiac arrhythmia in any of the participants. Among 34 individuals reaching basecamp at 5300 m, 32 participants climbed to 7900 m or higher, and 14 reached the summit of Mount Everest. A total of 45 primary end point–relevant events were recorded in 13 individuals (38.2%). Forty-three bradyarrhythmic events were documented in 13 individuals (38.2%) and 2 ventricular tachycardias in 2 individuals (5.9%). Nine arrhythmias (20%) in 5 participants occurred when climbers were using supplemental bottled oxygen, whereas 36 events (80%) in 11 participants occurred at lower altitudes when no supplemental bottled oxygen was used. The proportion of individuals with arrhythmia remained stable across levels of increasing altitude, while event rates per 24 hours numerically increased between 5300 m (0.16 per 24 hours) and 7300 m (0.37 per 24 hours) before decreasing again at higher altitudes, where supplemental oxygen was used. None of the study participants reported dizziness or syncope. Conclusion and Relevance In this study, more than 1 in 3 healthy individuals experienced cardiac arrhythmia during the climb of Mount Everest, thereby confirming the association between exposure to high altitude and incidence of cardiac arrhythmia. Future studies should explore the potential implications of these rhythm disturbances.

Variables Influencing the Pressure and Volume of the Pulmonary Circulation as Risk Factors for Developing High Altitude Pulmonary Edema (HAPE)

Acute changes in cardiac dimensions, function, and longitudinal mechanics in healthy individuals with and without high‐altitude induced pulmonary hypertension at 4559 m

Systemic Blood Predictors of Elevated Pulmonary Artery Pressure Assessed by Non-invasive Echocardiography After Acute Exposure to High Altitude: A Prospective Cohort Study

Evaluation and Management of the Individual with Recurrent High Altitude Pulmonary Edema

Risk factors underlying high-altitude pulmonary edema in the Ecuadorian Andes

Brain Natriuretic Peptide Levels and the Occurrence of Subclinical Pulmonary Edema in Healthy Lowlanders at High Altitude

Symposium review: high altitude travel with pulmonary vascular disease

Evaluation of High Altitude Interstitial Pulmonary Edema in Healthy Participants Using Rapid 4-View Lung Ultrasound Protocol During Staged Ascent to Everest Base Camp

Pediatric high‐altitude pulmonary edema and acute mountain sickness: Clinical features and risk determinants

Trends in the workload of the two high altitude aid posts in the Nepal Himalayas

Clinician's Corner: Counseling Patients with Pulmonary Vascular Disease Traveling to High Altitude

Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders

Identifying the Causes of Unexplained Dyspnea at High Altitude Using Normobaric Hypoxia with Echocardiography

Basic medical advice for travelers to high altitudes

Genetics of High-Altitude Pulmonary Edema

THE PREVALENCE AND RISK FACTORS OF HIGH-ALTITUDE PULMONARY HYPERTENSION AMONG THE HIGHLANDERS IN TIBETAN AREA

High-Altitude Pulmonary Edema in Two Pediatric Patients with Pre-Existing Lung Disease

Asymmetric and symmetric dimethylarginine in high altitude pulmonary hypertension (HAPH) and high altitude pulmonary edema (HAPE)

Using modified Fenn diagrams to assess ventilatory acclimatization during ascent to high altitude: Effect of acetazolamide

Risk of Cardiac Arrhythmias Among Climbers on Mount Everest

Clinico-epidemiological profile of high altitude pulmonary edema